Diabetes mellitus type 1 screening: Difference between revisions
Jump to navigation
Jump to search
m (Bot: Removing from Primary care) |
No edit summary |
||
| Line 8: | Line 8: | ||
==Screening== | ==Screening== | ||
According to the American diabetic association | * According to the American diabetic association screening for type 1 DM is not recommended. However, one should consider referring relatives of those with type 1 diabetes for antibody testing for risk assessment in the setting of a [http://www2 .diabetestrialnet.org clinical research study clincal study clinical research]. Higher-risk individuals may be tested, but only in the context of a clinical research setting.<ref name=":0" /> | ||
* Based on some studies, [[screening]] for [[diabetes mellitus type 1|diabetic]] [[patient|patients]] has some favorable effects. The following table is a summary of [[screening]] effects based on 6 pediatric studies:<ref name="pmid22060727">{{cite journal| author=Winkler C, Schober E, Ziegler AG, Holl RW| title=Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies. | journal=Pediatr Diabetes | year= 2012 | volume= 13 | issue= 4 | pages= 308-13 | pmid=22060727 | doi=10.1111/j.1399-5448.2011.00829.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22060727 }} </ref><ref name="pmid21972409">{{cite journal| author=Elding Larsson H, Vehik K, Bell R, Dabelea D, Dolan L, Pihoker C | display-authors=etal| title=Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. | journal=Diabetes Care | year= 2011 | volume= 34 | issue= 11 | pages= 2347-52 | pmid=21972409 | doi=10.2337/dc11-1026 | pmc=3198296 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21972409 }} </ref><ref name="pmid24823816">{{cite journal| author=Lundgren M, Sahlin Å, Svensson C, Carlsson A, Cedervall E, Jönsson B | display-authors=etal| title=Reduced morbidity at diagnosis and improved glycemic control in children previously enrolled in DiPiS follow-up. | journal=Pediatr Diabetes | year= 2014 | volume= 15 | issue= 7 | pages= 494-501 | pmid=24823816 | doi=10.1111/pedi.12151 | pmc=4190091 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24823816 }} </ref><ref name="pmid28127835">{{cite journal| author=Steck AK, Larsson HE, Liu X, Veijola R, Toppari J, Hagopian WA | display-authors=etal| title=Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls. | journal=Pediatr Diabetes | year= 2017 | volume= 18 | issue= 8 | pages= 794-802 | pmid=28127835 | doi=10.1111/pedi.12485 | pmc=5529265 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28127835 }} </ref> | |||
{| class="wikitable" | |||
!Study | |||
!'''Less DKA''' | |||
!'''Lower HbA1c''' | |||
!'''Lower insulin dose''' | |||
!'''Shorter hospitalization period''' | |||
|- | |||
|BABYDIAB and Munich | |||
| + | |||
| + | |||
| - | |||
| + | |||
|- | |||
|DiPiS | |||
| + | |||
| + | |||
| - | |||
|Not determined | |||
|- | |||
|TEDDY | |||
| + | |||
| + | |||
| + | |||
|Not determined | |||
|- | |||
|DAISY | |||
| + | |||
| + | |||
| + | |||
| + | |||
|- | |||
|DIPP | |||
| + | |||
| + | |||
|Not determined | |||
|Not determined | |||
|} | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
| Line 15: | Line 54: | ||
{{WS}} | {{WS}} | ||
[[Category: | [[Category:Screening]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
Revision as of 15:11, 11 September 2020
|
Diabetes mellitus type 1 Microchapters |
|
Differentiating Diabetes mellitus type 1 from other Diseases |
|
Diagnosis |
|
Treatment |
|
Cardiovascular Disease and Risk Management |
|
Case Studies |
|
Diabetes mellitus Main page |
|
Patient Information |
|---|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Vishal Devarkonda, M.B.B.S[2]
Overview
According to the American Diabetic Association, screening for type 1 DM is not recommended.[1]
Screening
- According to the American diabetic association screening for type 1 DM is not recommended. However, one should consider referring relatives of those with type 1 diabetes for antibody testing for risk assessment in the setting of a clinical research. Higher-risk individuals may be tested, but only in the context of a clinical research setting.[1]
- Based on some studies, screening for diabetic patients has some favorable effects. The following table is a summary of screening effects based on 6 pediatric studies:[2][3][4][5]
| Study | Less DKA | Lower HbA1c | Lower insulin dose | Shorter hospitalization period |
|---|---|---|---|---|
| BABYDIAB and Munich | + | + | - | + |
| DiPiS | + | + | - | Not determined |
| TEDDY | + | + | + | Not determined |
| DAISY | + | + | + | + |
| DIPP | + | + | Not determined | Not determined |
References
- ↑ 1.0 1.1 http://care.diabetesjournals.org/content/suppl/2015/12/21/39.Supplement_1.DC2/2016-Standards-of-Care.pdf
- ↑ Winkler C, Schober E, Ziegler AG, Holl RW (2012). "Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies". Pediatr Diabetes. 13 (4): 308–13. doi:10.1111/j.1399-5448.2011.00829.x. PMID 22060727.
- ↑ Elding Larsson H, Vehik K, Bell R, Dabelea D, Dolan L, Pihoker C; et al. (2011). "Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up". Diabetes Care. 34 (11): 2347–52. doi:10.2337/dc11-1026. PMC 3198296. PMID 21972409.
- ↑ Lundgren M, Sahlin Å, Svensson C, Carlsson A, Cedervall E, Jönsson B; et al. (2014). "Reduced morbidity at diagnosis and improved glycemic control in children previously enrolled in DiPiS follow-up". Pediatr Diabetes. 15 (7): 494–501. doi:10.1111/pedi.12151. PMC 4190091. PMID 24823816.
- ↑ Steck AK, Larsson HE, Liu X, Veijola R, Toppari J, Hagopian WA; et al. (2017). "Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls". Pediatr Diabetes. 18 (8): 794–802. doi:10.1111/pedi.12485. PMC 5529265. PMID 28127835.